To help you advance your research, our stem cell scientists from around the world have created these presentations on cutting-edge stem cell technologies.
View our most recent webinars:
Disease model development: a highly efficient and optimized workflow for editing human iPSCs »
A breakthrough solution for long-term intrinsic clearance studies of low-clearance drugs »
In this webinar, Philip Dalsbecker (Goksör-Adiels group) covers data demonstrating functional on-chip maturation of iPSCs to hepatocytes, as well as initial data showing how further optimization of the platform can give great insight into the state of the cultured cells, on single-cell and population levels.
In this webinar, Dr. Chris Sontag (Takara Bio USA, Inc.) presents data showing a new workflow for footprint-free editing via efficient delivery of Cas9/sgRNA ribonucleoprotein (RNP) complexes and single-cell cloning of hiPS cells using a modified DEF-CS culture protocol, which results in a high number of edited and expandable hiPS clones that maintain the hallmarks of pluripotency.
Dr. Christopher Sontag of Takara Bio USA, Inc. introduces single-cell cloning with the Cellartis DEF-CS 500 Culture System to create clonal hiPS cell lines. He presents data comparing the DEF-CS culture system and competitors’ systems for single-cell cloning: the DEF-CS system enables the highest survival and maintenance of pluripotency.
Ingrid Rydström, MSc, of Takara Bio Europe AB, describes solutions for maintaining human induced pluripotent stem cell lines. The Cellartis DEF-CS 500 Culture System enables the high-purity culture of hiPS cells under feeder-free, defined conditions and allows single-cell enzymatic passaging, providing unparalleled experimental flexibility. Learn about the protocol for using the DEF-CS culture system with your cells, includes passaging, guidelines for cell line transfer from other systems, and applications.
Dr. Annika Asplund (Takara Bio Europe AB) presents data generated with human iPSC-derived hepatocytes showing how we can pave the way for better disease models with more consistent performance over time. This innovative tool represents an important step toward advancing the discovery of new treatments for metabolic and infectious disease, reducing the incidence of drug-induced liver injury, and developing new strategies for liver regeneration and transplantation.
Dr. Liz Quinn of Takara Bio USA, Inc. describes the Cellartis iPS Cell to Hepatocyte Differentiation System, which provides a highly reproducible and robust hepatocyte differentiation protocol, validated on 25 different hiPS cell lines without the need for optimization. Ideal for drug metabolism and safety studies, you can start with any patient-specific hiPS cell lines and develop panels of hiPSC-derived hepatocytes with diverse genetic backgrounds.
Dr. Christopher Sontag of Takara Bio USA, Inc. describes how Cellartis hiPS beta cells can speed up your drug-discovery process. This functional iPSC-derived cell model, suitable for in vitro assays, helps you understand disease biology and find better drug candidates. These cells are ideal for diabetes research because they express mature beta-cell markers (e.g., insulin, MAFA, and NKX6.1) and demonstrate glucose-stimulated insulin secretion (GSIS) after cryopreservation.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
©2019 Takara Bio Inc. All Rights Reserved.
Region - North America Privacy Policy Terms and Conditions Terms of Use
Towards a 3D liver mimicry: the liver lobule on a chip
In this webinar, Philip Dalsbecker (Goksör-Adiels group) covers data demonstrating functional on-chip maturation of iPSCs to hepatocytes, as well as initial data showing how further optimization of the platform can give great insight into the state of the cultured cells, on single-cell and population levels.
Footprint-free gene editing using CRISPR/Cas9 and single-cell cloning of edited human iPS cells
In this webinar, Dr. Chris Sontag (Takara Bio USA, Inc.) presents data showing a new workflow for footprint-free editing via efficient delivery of Cas9/sgRNA ribonucleoprotein (RNP) complexes and single-cell cloning of hiPS cells using a modified DEF-CS culture protocol, which results in a high number of edited and expandable hiPS clones that maintain the hallmarks of pluripotency.
Single-cell cloning of human iPS cells—an optimized culture system for creating highly pluripotent, edited clonal lines
Dr. Christopher Sontag of Takara Bio USA, Inc. introduces single-cell cloning with the Cellartis DEF-CS 500 Culture System to create clonal hiPS cell lines. He presents data comparing the DEF-CS culture system and competitors’ systems for single-cell cloning: the DEF-CS system enables the highest survival and maintenance of pluripotency.
A complete culture system for human induced pluripotent stem cells
Ingrid Rydström, MSc, of Takara Bio Europe AB, describes solutions for maintaining human induced pluripotent stem cell lines. The Cellartis DEF-CS 500 Culture System enables the high-purity culture of hiPS cells under feeder-free, defined conditions and allows single-cell enzymatic passaging, providing unparalleled experimental flexibility. Learn about the protocol for using the DEF-CS culture system with your cells, includes passaging, guidelines for cell line transfer from other systems, and applications.
Using human iPSC-derived hepatocytes with advanced functionality and longevity: innovative tools for disease modeling and drug discovery
Dr. Annika Asplund (Takara Bio Europe AB) presents data generated with human iPSC-derived hepatocytes showing how we can pave the way for better disease models with more consistent performance over time. This innovative tool represents an important step toward advancing the discovery of new treatments for metabolic and infectious disease, reducing the incidence of drug-induced liver injury, and developing new strategies for liver regeneration and transplantation.
Human iPSC-derived hepatocytes—innovative tools for disease modeling, drug discovery, and liver toxicity studies
Dr. Liz Quinn of Takara Bio USA, Inc. describes the Cellartis iPS Cell to Hepatocyte Differentiation System, which provides a highly reproducible and robust hepatocyte differentiation protocol, validated on 25 different hiPS cell lines without the need for optimization. Ideal for drug metabolism and safety studies, you can start with any patient-specific hiPS cell lines and develop panels of hiPSC-derived hepatocytes with diverse genetic backgrounds.
Insulin-secreting human iPSC-derived beta cells for reproducibly modeling and understanding disease
Dr. Christopher Sontag of Takara Bio USA, Inc. describes how Cellartis hiPS beta cells can speed up your drug-discovery process. This functional iPSC-derived cell model, suitable for in vitro assays, helps you understand disease biology and find better drug candidates. These cells are ideal for diabetes research because they express mature beta-cell markers (e.g., insulin, MAFA, and NKX6.1) and demonstrate glucose-stimulated insulin secretion (GSIS) after cryopreservation.
